Amphion Innovations plc

Subsidiary Company DataTern Receives Favourable Appeal Ruling

London and New York, 5 January 2015- The Board of Amphion, a developer of medical, life science and technology businesses, announces today that DataTern Inc. (“DataTern”), a wholly-owned subsidiary of the Company, has received a favorable decision on its appeal to the United States Court of Appeals for the Federal Circuit.  The appeal arose out of the United States District Court for the District of Massachusetts grant of summary judgment that the defendant, MicroStrategy, Inc., and several other defendants, did not infringe U.S. Patent No. 6,101,502 (the “‘502 Patent’”).    

In concluding that DataTern’s claim construction was correct, and that the District Court had erred in using a different more narrow interpretation, the Federal Circuit vacated the summary judgment and remanded the case back to the District Court so that DataTern may proceed with its contentions that MicroStrategy, and several other defendants, infringe the ‘502 Patent’ under the corrected claim construction.  MicroStrategy sells business intelligence and analytics software platforms used by other defendants.

Richard Morgan, CEO of Amphion, said: "This result confirms our view that the ‘502 Patent’ has been infringed.  The ‘502 Patent’ is directed to how object oriented software applications access data stored in a relational database.  Such applications are widely used and most databases in use today are relational databases.  We continue to believe that companies that are using or want to use our patented technology will wish to enter into equitable licensing agreements.  Our goal remains to generate a fair and reasonable return on the very substantial investment we have made over many years in the development of this innovative technology."

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Yellow Jersey PR
Dominic Barretto / Fiona Walker
+44 7768 537 739

Panmure Gordon Limited
Freddy Crossley / Fred Walsh (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 020 7886 2500

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: